=== PAGE 5 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Jessica Chmielewski
Edenbridge Pharmaceuticals, LLC DBA Dexcel Pharma USA
NDA 211379/MA 33

Page 5

Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 0078 under NDA 211379. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Louiza Bako, PharmD
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

{See appended electronic signature page}

Jina Kwak, PharmD, RAC
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Reference ID: 5523412
